Allergan in $5 million opioids settlement with two Ohio states

2 September 2019

Ireland-incorporated Allergan (NYSE: AGN) on Friday announced that, along with its US subsidiaries, has reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid multidistrict litigation.

As part of the agreement, Allergan will pay $1.9 million to Summit County, Ohio, and $3.1 million to Cuyahoga County, Ohio.

The settlement resolves all claims against Allergan in connection with the upcoming October 2019 Cleveland trial. The company believes that settling with these plaintiffs is in its interest in light of anticipated time and defense costs for this first multi-defendant bellwether trial in the federal multidistrict litigation. The company is seeking indemnification from other parties relating to one of its products involved in the litigation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK